Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL J LEONARD IV

Allopathic & Osteopathic Physicians Pediatrics

NPI
1801058243
CMS profile
500103
Location
HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$33.08

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $33.08 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Supernus Pharmaceuticals, Inc. $20.49 1
PFIZER INC. $12.59 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL J LEONARD IV

NPI 1801058243 · CMS profile ID 500103

Allopathic & Osteopathic Physicians / Pediatrics

HASTINGS, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL J LEONARD IV, NPI 1801058243, CMS profile ID 500103, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801058243?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $33.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Supernus Pharmaceuticals, Inc. $20.4911/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053276887 CMS
PFIZER INC. $12.0509/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049130133 CMS
PFIZER INC. $0.5409/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050416791 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $13.39 1
PY2023 $33.08 3
PY2024 $109.51 4
PY2025 $27.88 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,874.99 57
PY2024 Principal investigator $439,732.84 105
PY2023 Recipient $7,049.40 6
PY2023 Principal investigator $530,880.36 269
PY2022 Principal investigator $1,225,410.93 120
PY2021 Principal investigator $1,389,610.75 61
PY2020 Principal investigator $5,537.42 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

275 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,061.15 12/31/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide No dispute reported 06/30/2026 998414373
Principal investigator 1 ABBVIE INC. $903.75 12/31/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998414375
Principal investigator 1 Merck Sharp & Dohme LLC $15,258.65 12/31/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1042492811
Principal investigator 1 GlaxoSmithKline, LLC. $759.61 12/22/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006252801
Principal investigator 1 ModernaTX, Inc. $101.25 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040222263
Principal investigator 1 Merck Sharp & Dohme LLC $76,450.00 12/18/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants No dispute reported 06/30/2026 1042492809
Principal investigator 1 ModernaTX, Inc. $505.68 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040191147
Principal investigator 1 ModernaTX, Inc. $470.21 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040193641
Principal investigator 1 ModernaTX, Inc. $470.21 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040193913
Principal investigator 1 ModernaTX, Inc. $1,136.03 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040195773
Principal investigator 1 ModernaTX, Inc. $505.68 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040197037
Principal investigator 1 ModernaTX, Inc. $1,257.53 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040197601
Principal investigator 1 ModernaTX, Inc. $470.21 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040197615
Principal investigator 1 ModernaTX, Inc. $505.68 12/14/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040198151
Principal investigator 1 ABBVIE INC. $7,391.25 12/04/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998409847
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040010605
Principal investigator 1 ModernaTX, Inc. $151.25 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040010691
Principal investigator 1 ModernaTX, Inc. $164.75 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040010777
Principal investigator 1 ModernaTX, Inc. $197.64 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040010819
Principal investigator 1 ModernaTX, Inc. $244.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040010825
Principal investigator 1 ModernaTX, Inc. $243.81 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040010833
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040012421
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040014895
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040018025
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040022479
Principal investigator 1 ModernaTX, Inc. $158.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040025357
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040032051
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040032061
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040037795
Principal investigator 1 ModernaTX, Inc. $151.25 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040037805
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040047223
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040047235
Principal investigator 1 ModernaTX, Inc. $244.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040055401
Principal investigator 1 ModernaTX, Inc. $157.41 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040055411
Principal investigator 1 ModernaTX, Inc. $164.75 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040057881
Principal investigator 1 ModernaTX, Inc. $197.64 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040057889
Principal investigator 1 ModernaTX, Inc. $164.75 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040071931
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040071941
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040071951
Principal investigator 1 ModernaTX, Inc. $243.81 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040076745
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040076755
Principal investigator 1 ModernaTX, Inc. $38.74 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040079825
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040087399
Principal investigator 1 ModernaTX, Inc. $197.64 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040092265
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040097039
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040097047
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040102337
Principal investigator 1 ModernaTX, Inc. $43.20 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040104997
Principal investigator 1 ModernaTX, Inc. $158.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040137287
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040139753
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040145803
Principal investigator 1 ModernaTX, Inc. $126.22 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040149303
Principal investigator 1 ModernaTX, Inc. $197.64 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040151635
Principal investigator 1 ModernaTX, Inc. $139.72 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040155507
Principal investigator 1 ModernaTX, Inc. $157.41 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040162261
Principal investigator 1 ModernaTX, Inc. $164.75 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040164773
Principal investigator 1 ModernaTX, Inc. $157.41 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1040173369
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040176829
Principal investigator 1 ModernaTX, Inc. $56.19 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040176843
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973489
Principal investigator 1 ModernaTX, Inc. $1,361.29 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973507
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973513
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973519
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973525
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974397
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974403
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974411
Principal investigator 1 ModernaTX, Inc. $505.68 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974417
Principal investigator 1 ModernaTX, Inc. $1,778.76 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974423
Principal investigator 1 ModernaTX, Inc. $1,361.29 11/29/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039974429
Principal investigator 1 ModernaTX, Inc. $348.71 11/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039973567
Principal investigator 1 ModernaTX, Inc. $348.71 11/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039973573
Principal investigator 1 ModernaTX, Inc. $348.71 11/24/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039973641
Principal investigator 1 PFIZER INC. $4.00 11/24/2023 Non-covered Recipient Entity
1
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046179981
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 11/20/2023 Non-covered Recipient Entity
Meridian Clinical Research,LLC
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 1035880273
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 11/20/2023 Non-covered Recipient Entity
Meridian Clinical Research,LLC
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants No dispute reported 06/30/2026 1035880285
Principal investigator 1 ModernaTX, Inc. $135.00 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973483
Principal investigator 1 ModernaTX, Inc. $236.25 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973501
Principal investigator 1 ModernaTX, Inc. $43.20 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973543
Principal investigator 1 ModernaTX, Inc. $236.25 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973555
Principal investigator 1 ModernaTX, Inc. $43.20 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973561
Principal investigator 1 ModernaTX, Inc. $74.25 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973597
Principal investigator 1 ModernaTX, Inc. $228.42 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973603
Principal investigator 1 ModernaTX, Inc. $68.85 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973621
Principal investigator 1 ModernaTX, Inc. $135.00 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973629
Principal investigator 1 ModernaTX, Inc. $68.85 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973647
Principal investigator 1 ModernaTX, Inc. $74.25 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973653
Principal investigator 1 ModernaTX, Inc. $228.42 11/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039973659
Principal investigator 1 PFIZER INC. $2,068.75 11/16/2023 Non-covered Recipient Entity
1
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046176781
Principal investigator 1 GlaxoSmithKline, LLC. $9.63 11/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253045
Principal investigator 1 GlaxoSmithKline, LLC. $772.79 11/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253065
Principal investigator 1 ModernaTX, Inc. $1,529.00 11/15/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040218937
Principal investigator 1 ABBVIE INC. $2,430.00 11/08/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998407275
Principal investigator 1 ModernaTX, Inc. $337.50 11/08/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040219221
Principal investigator 1 ModernaTX, Inc. $1,117.80 11/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040219233
Principal investigator 1 Amgen Inc. $23,255.40 11/02/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH, LLC
Phase P3 Pediatric Study (EM) No dispute reported 06/30/2026 1029657989
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Double-Blind, Randomized, Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214SARS-CoV-2 Vaccine in Healthy Babies aged 0 to 6 months. No dispute reported 06/30/2026 1040205665
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039918033
Principal investigator 1 ModernaTX, Inc. $505.68 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039922257
Principal investigator 1 ModernaTX, Inc. $348.71 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039926371
Principal investigator 1 ModernaTX, Inc. $348.71 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039928721
Principal investigator 1 ModernaTX, Inc. $505.68 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039929519
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039933975
Principal investigator 1 ModernaTX, Inc. $505.68 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039933985
Principal investigator 1 ModernaTX, Inc. $1,257.53 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039934393
Principal investigator 1 ModernaTX, Inc. $505.68 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039937755
Principal investigator 1 ModernaTX, Inc. $1,427.63 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039941375
Principal investigator 1 ModernaTX, Inc. $1,257.53 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039941385
Principal investigator 1 ModernaTX, Inc. $505.68 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039942177
Principal investigator 1 ModernaTX, Inc. $1,427.63 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039946553
Principal investigator 1 ModernaTX, Inc. $348.71 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039947927
Principal investigator 1 ModernaTX, Inc. $1,361.29 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039951541
Principal investigator 1 ModernaTX, Inc. $1,427.63 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039952617
Principal investigator 1 ModernaTX, Inc. $1,361.29 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039958863
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910299
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910367
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910379
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910395
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910463
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910479
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910549
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910589
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910629
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910669
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910779
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910875
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910905
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039910975
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039911193
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039911261
Principal investigator 1 ModernaTX, Inc. $1,778.76 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039911407
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039911625
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912401
Principal investigator 1 ModernaTX, Inc. $1,482.79 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912443
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912457
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912581
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912777
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912837
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912849
Principal investigator 1 ModernaTX, Inc. $505.68 10/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039912959
Recipient PFIZER INC. $2.00 10/05/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045940103
Recipient PFIZER INC. $916.75 10/05/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046003695
Principal investigator 1 ModernaTX, Inc. $43.20 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039899501
Principal investigator 1 ModernaTX, Inc. $74.25 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039903107
Principal investigator 1 ModernaTX, Inc. $68.85 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039904269
Principal investigator 1 ModernaTX, Inc. $135.00 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039905521
Principal investigator 1 ModernaTX, Inc. $228.42 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039906085
Principal investigator 1 ModernaTX, Inc. $384.75 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039906819
Principal investigator 1 ModernaTX, Inc. $234.90 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039908161
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039909933
Principal investigator 1 ModernaTX, Inc. $7,700.60 09/27/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1040217271
Principal investigator 1 ModernaTX, Inc. $37.50 09/20/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040217055
Principal investigator 1 GlaxoSmithKline, LLC. $386.73 09/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1006253019
Recipient PFIZER INC. $1,833.50 09/14/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046021787
Principal investigator 1 ModernaTX, Inc. $16,087.27 09/13/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040217091
Principal investigator 1 ModernaTX, Inc. $1,404.00 09/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040216417
Principal investigator 1 ModernaTX, Inc. $1,459.15 09/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040216369
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Study to Evaluate the Safety and Immunogenicity of the mRNA-1273.214 COVID-19 Vaccine in Healthy Children Between 6 Months to Less Than 6 Years of Age No dispute reported 06/30/2026 1040223677
Principal investigator 1 ModernaTX, Inc. $303.75 08/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040215911
Principal investigator 1 ModernaTX, Inc. $11.00 08/25/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203793
Principal investigator 1 ModernaTX, Inc. $600.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 1040206661
Principal investigator 1 ModernaTX, Inc. $10,359.90 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040215887
Principal investigator 1 ModernaTX, Inc. $7,241.90 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040216561
Principal investigator 1 ABBVIE INC. $4,750.00 08/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998396291
Principal investigator 1 ModernaTX, Inc. $3,309.80 08/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 1040214924
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040203889
Principal investigator 1 ModernaTX, Inc. $2,000.00 08/10/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1039855455
Principal investigator 1 ABBVIE INC. $15,000.00 08/09/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation No dispute reported 06/30/2026 998393515
Principal investigator 1 ModernaTX, Inc. $1,875.11 08/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age No dispute reported 06/30/2026 1040214479
Principal investigator 1 GlaxoSmithKline, LLC. $6,952.91 08/04/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1006253039
Recipient PFIZER INC. $576.00 08/03/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046307983
Principal investigator 1 ModernaTX, Inc. $8,367.80 07/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040214085
Principal investigator 1 ModernaTX, Inc. $2,392.20 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213433
Principal investigator 1 GlaxoSmithKline, LLC. $45.84 07/12/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006252795
Principal investigator 1 GlaxoSmithKline, LLC. $981.49 07/07/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1006252815
Principal investigator 1 ModernaTX, Inc. $475.94 07/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040212295
Principal investigator 1 PFIZER INC. $1,432.60 07/06/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046044057
Principal investigator 1 PFIZER INC. $915.80 07/06/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046220439
Principal investigator 1 ModernaTX, Inc. $2,000.00 06/21/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1040206601
Principal investigator 1 ModernaTX, Inc. $14,500.00 06/21/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1040212443
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/21/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants No dispute reported 06/30/2026 1040212455
Principal investigator 1 ModernaTX, Inc. $4,545.30 06/21/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040212879
Principal investigator 1 ModernaTX, Inc. $2.27 06/16/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042151227
Principal investigator 1 PFIZER INC. $916.75 06/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1045989921
Principal investigator 1 ModernaTX, Inc. $2,194.29 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838831
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838853
Principal investigator 1 ModernaTX, Inc. $505.68 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838873
Principal investigator 1 ModernaTX, Inc. $505.68 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838893
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838913
Principal investigator 1 ModernaTX, Inc. $505.68 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838933
Principal investigator 1 ModernaTX, Inc. $505.68 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838955
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838971
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039838993
Principal investigator 1 ModernaTX, Inc. $2,194.29 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839013
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839031
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839049
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839069
Principal investigator 1 ModernaTX, Inc. $1,482.79 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839091
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839113
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839129
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839147
Principal investigator 1 ModernaTX, Inc. $1,482.79 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839169
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839197
Principal investigator 1 ModernaTX, Inc. $12.15 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1039839217
Principal investigator 1 GlaxoSmithKline, LLC. $1,722.18 06/09/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006252809
Principal investigator 1 GlaxoSmithKline, LLC. $75.77 06/09/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006252821
Principal investigator 1 ModernaTX, Inc. $766.80 06/09/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040211245
Principal investigator 1 ModernaTX, Inc. $3,670.65 06/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040211147
Principal investigator 1 ModernaTX, Inc. $51.35 05/19/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042151209
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040610987
Principal investigator 1 ModernaTX, Inc. $505.68 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611003
Principal investigator 1 ModernaTX, Inc. $1,016.00 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611147
Principal investigator 1 ModernaTX, Inc. $505.68 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611233
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611249
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611281
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611297
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611313
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611329
Principal investigator 1 ModernaTX, Inc. $505.68 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611345
Principal investigator 1 ModernaTX, Inc. $505.68 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611429
Principal investigator 1 ModernaTX, Inc. $2,194.29 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611577
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611711
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611827
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611845
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040611929
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612023
Principal investigator 1 ModernaTX, Inc. $2,194.29 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612039
Principal investigator 1 ModernaTX, Inc. $505.68 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612143
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612159
Principal investigator 1 ModernaTX, Inc. $10,000.00 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612253
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612358
Principal investigator 1 ModernaTX, Inc. $12.15 05/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040612459
Principal investigator 1 GlaxoSmithKline, LLC. $487.61 05/17/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253025
Principal investigator 1 ModernaTX, Inc. $766.80 05/17/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040210135
Recipient PFIZER INC. $1,338.55 05/11/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046159433
Principal investigator 1 ModernaTX, Inc. $4,171.50 05/10/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040210099
Recipient PFIZER INC. $2,382.60 05/04/2023 Covered Recipient Physician A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046007575
Principal investigator 1 ModernaTX, Inc. $490.05 05/03/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040210063
Principal investigator 1 ModernaTX, Inc. $51.35 05/02/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042151215
Principal investigator 1 GlaxoSmithKline, LLC. $1,939.19 05/01/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253033
Principal investigator 1 ModernaTX, Inc. $189.26 05/01/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 2, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults 18 to 49 Years of Age No dispute reported 06/30/2026 1042151221
Principal investigator 1 ModernaTX, Inc. $6,901.20 04/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040209945
Principal investigator 1 ModernaTX, Inc. $1,437.75 04/21/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040209931
Principal investigator 1 ModernaTX, Inc. $1,815.75 04/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040209873
Principal investigator 1 ModernaTX, Inc. $2,627.10 04/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040210653
Principal investigator 1 GlaxoSmithKline, LLC. $5,783.06 04/06/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, DOSE FINDING STUDY TO No dispute reported 06/30/2026 1006252789
Principal investigator 1 ModernaTX, Inc. $2,346.50 04/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 1040210243
Principal investigator 1 ModernaTX, Inc. $11,537.00 04/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040210617
Principal investigator 1 ModernaTX, Inc. $3,163.05 03/29/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040769164
Principal investigator 1 ModernaTX, Inc. $2,500.00 03/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040520723
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1040524037
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $2,412.65 03/16/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046328659
Principal investigator 1 ModernaTX, Inc. $2,948.40 03/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040769087
Principal investigator 1 ModernaTX, Inc. $6.81 03/10/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042151203
Principal investigator 1 Amgen Inc. $13,288.80 03/09/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH, LLC
Ph3 Pediatric CM Study No dispute reported 06/30/2026 1029656365
Principal investigator 1 ModernaTX, Inc. $32,208.30 03/03/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040767577
Principal investigator 1 GlaxoSmithKline, LLC. $8,446.48 03/01/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253059
Principal investigator 1 ModernaTX, Inc. $766.80 03/01/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040767561
Principal investigator 1 ModernaTX, Inc. $1,352.00 02/22/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040759561
Principal investigator 1 ModernaTX, Inc. $996.30 02/22/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040765727
Principal investigator 1 ModernaTX, Inc. $42.50 02/17/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042151197
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,338.55 02/16/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046096361
Principal investigator 1 ModernaTX, Inc. $27.00 02/15/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040765709
Principal investigator 1 ModernaTX, Inc. $19,693.80 02/10/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040765693
Principal investigator 1 ModernaTX, Inc. $11,452.05 02/08/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040765661
Principal investigator 1 ModernaTX, Inc. $5,421.60 02/03/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040765645
Principal investigator 1 ModernaTX, Inc. $993.60 01/27/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040764599
Principal investigator 1 GlaxoSmithKline, LLC. $10,987.59 01/25/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 2B, RANDOMIZED, OBSERVER-BLINDED TRIAL TO DESCRIBE THE SAFETY, No dispute reported 06/30/2026 1006253071
Principal investigator 1 ModernaTX, Inc. $827.45 01/20/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged No dispute reported 06/30/2026 1040764997
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $4,618.90 01/19/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046316413
Principal investigator 1 ModernaTX, Inc. $3,861.00 01/18/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040764581
Principal investigator 1 ModernaTX, Inc. $1,701.24 01/12/2023 Non-covered Recipient Entity
Meridian Clinical Research, LLC
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months No dispute reported 06/30/2026 1042151191
Principal investigator 1 ModernaTX, Inc. $1,012.50 01/11/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040762755
Principal investigator 1 GlaxoSmithKline, LLC. $565.50 01/04/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A PHASE II, OBSERVER-BLIND, RANDOMIZED, CONTROLLED STUDY TO EVALUATE T No dispute reported 06/30/2026 1006253053
Principal investigator 1 ModernaTX, Inc. $1,118.98 01/04/2023 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040762739